Ultragenyx (RARE) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue reached $147 million, up 36% year-over-year, driven by strong growth in Crysvita, Dojolvi, and Evkeeza sales, with robust demand across all major products and geographies.

• Four approved products across five indications in ten years, with the largest clinical pipeline in rare disease and rapid development timelines averaging 5.5 years from clinic to approval.

• Multiple late-stage clinical programs advanced, with positive data readouts and key regulatory milestones achieved, including agreements with the FDA for accelerated approval pathways.

• The company is positioned for multiple regulatory submissions and pivotal data readouts over the next 6–18 months, marking a significant inflection point.

• Net loss for Q2 2024 was $132 million ($1.52 per share), an improvement from $160 million ($2.25 per share) in Q2 2023.

Financial highlights

• Q2 2024 total revenue was $147 million, with Crysvita contributing $114 million, Dojolvi $19 million, Evkeeza $8 million, and Mepsevii $6 million.

• Net loss for Q2 2024 was $132 million, or $1.52 per share.

• Operating expenses for Q2 2024 totaled $263 million, including $162 million in R&D and $81 million in SG&A.

• Cash, cash equivalents, and marketable securities stood at $874 million as of June 30, 2024, bolstered by $381 million in net proceeds from a June offering.

• Net cash used in operations was $77 million for Q2 and $268 million for the first half of 2024.

Outlook and guidance

• 2024 total revenue guidance raised to $530–$550 million, reflecting strong performance across the portfolio.

• Crysvita revenue expected toward the upper end of $375–$400 million; Dojolvi revenue guidance maintained at $75–$80 million.

• Net cash used in operations for 2024 expected to remain below $400 million.

• Annual operating expenses anticipated to remain stable or decrease as cost management continues.

• Multiple pivotal data readouts and regulatory milestones expected in late 2024 and 2025.